etoposide has been researched along with gossypol in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Johnson, DE; Land, S; Miranda, MB; Oliver, CL; Shangary, S; Wang, S | 1 |
| Guang, ZZ; Jiang, WQ; Li, ZM; Liu, ZC; Yang, DJ; Zhou, JM; Zhu, XF; Zhu, ZY | 1 |
| Alberti, DB; Eickhoff, J; Keppen, M; Kolesar, JM; Liu, G; Marnocha, RM; Mohammed, TA; Schelman, WR; Takebe, N; Traynor, AM; Wilding, G | 1 |
| Chang, HH; Chang, JY; Chen, HH; Chen, YT; Chuang, YJ; Kuo, CC; Tang, YC; Yao, JY | 1 |
1 trial(s) available for etoposide and gossypol
| Article | Year |
|---|---|
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Gossypol; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2014 |
5 other study(ies) available for etoposide and gossypol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.
Topics: Apoptosis; bcl-X Protein; Cell Survival; Etoposide; Gossypol; Humans; Jurkat Cells; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Transfection | 2005 |
Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Cyclophosphamide; Doxorubicin; Drug Synergism; Etoposide; Gossypol; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisolone; Tumor Suppressor Protein p53; Vincristine | 2008 |
A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells.
Topics: Antioxidant Response Elements; Cisplatin; Etoposide; Gossypol; Humans; Neoplasms; NF-E2-Related Factor 2 | 2021 |